Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of ...

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

WARNING: The following story contains spoilers about the fifth episode of The Handmaid's Tale's sixth and final season, ...

(GILD) on Thursday reported first-quarter earnings of $1.32 billion. The Foster City, California-based company said it had net income of $1.04 per share. Earnings, adjusted for costs related to ...

"The Handmaid's Tale" may be coming to an end, but the world of Gilead is not with a sequel, "The Testaments," in production ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

President Donald Trump's energy security council plans to host a summit in Alaska in early June, when it hopes Japanese and ...

Looking ahead, Gilead Sciences cut its full-year earnings outlook to $5.65 to $6.05 a share from a prior range of $5.95 to $6.35 a share. Analysts had been expecting full-year earnings of $6.22. The ...

Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...

The Gilead Road Bridge over I-77 in Huntersville, NC, will be closed from May 2 at 9 p.m. to May 5 at 6 a.m. for interchange ...